Avacta Group (AVCT)

 

AVCT Share PerformanceMore

52 week high98.00 26/05/17
52 week low28.00 11/05/18
52 week change -55.00 (-63.22%)
4 week volume992,815 26/04/18
price32.00
price date1527003942
close29.50

Media for (AVCT)

Presenter: Dr. Alastair Smith
01/08/2014
Presenter: Dr. Alastair Smith
07/05/2014

Latest NewsMore

Avacta hails encouraging results from FIT Biotech collaboration

Avacta Group said a research collaboration with Finland's FIT Biotech had produced 'very encouraging' data relating to its...

Successful Outcome of Study with FIT Biotech

RNS Number: 7844O Avacta Group PLC 22 May 2018 22 May 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Successful Outcome of "Gene Delivery" Collaboration with FIT Biotech Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits Avacta Group plc (AIM: AVCT), the develop...

Holding(s) in Company

RNS Number: 6341M Avacta Group PLC 30 April 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Avacta Group PLC 1...

Avacta (AVCT): Commendable rate of progress

Hardman & Co Research Hardman & Co Research: Avacta (AVCT): Commendable rate of progress 17-Apr-2018 / 07:15 GMT/BST Hardman & Co Research: Commendable rate of progress Avacta is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology, w...

Avacta Group net losses widen as costs rise

Avacta Group, reported Monday a wider half year net loss of 4m, compared with a loss of 3.4m the previous the year, weig...

Interim Results

RNS Number: 9356K Avacta Group PLC 16 April 2018 16 April 2018 Avacta Group plc ("Avacta", the "Company" or the "Group") Interim Results for the Period Ended 31 January 2018 Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces its unaudited interim results for the period ended 31 January 2018. Operatin...

Issue of Equity

RNS Number: 3083K Avacta Group PLC 09 April 2018 9 April 2018 Avacta Group plc ("Avacta", "the Group" or "the Company") Issue of Equity Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that application has been made for 10,345 new ordinary shares of 10p each (the "New Ordinary Shares") to be ad...

Avacta to Present at Investor Forum

RNS Number: 3024J Avacta Group PLC 29 March 2018 29 March 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to Present at Proactive Investors One2One Investor Forum Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, is pleased to announce that the Group's Chief Executive, Alastair Sm...

Fundamental DataMore

EPS-6.86
Dividend yield0 %

Latest discussion posts More

Users' HoldingsMore

Users who hold Avacta Group also hold..

Codes & Symbols

ISINGB00BYYW9G87
SymbolsAVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT